Apellis Pharmaceuticals Inc (OQ:APLS)
Business Focus: Biopharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 100 Fifth Avenue WALTHAM MA 02451 |
| Tel: | 1-617-5998178 |
| Website: | https://apellis.com |
| IR: | See website |
| Key People | ||
| Cedric Francois President, Chief Executive Officer, Co-Founder, Director | Mark Delong Chief Business and Strategy Officer | Pascal Deschatelets Co-Founder, Chief Scientific Officer |
| Timothy Sullivan Chief Financial Officer, Treasurer | Nur Nicholson Chief Technical Operations Officer | Adam J. Townsend Chief Operating Officer |
| Karen Lewis Chief People Officer | James G. Chopas Chief Accounting Officer, Vice President, Corporate Controller | David O. Watson General Counsel | Caroline Baumal Chief Medical Officer |
| Business Overview |
| Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company's approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom. |
| Financial Overview |
| For the three months ended 31 March 2024, Apellis Pharmaceuticals Inc revenues increased from $44.8M to $172.3M. Net loss decreased 63% to $66.4M. Revenues reflect SYFOVRE segment increase from $18.4M to $137.5M, EMPAVELI segment increase of 25% to $25.6M. Lower net loss reflects Compensation and related personnel costs decrease of 35% to $32.5M (expense), Research and Development - Balancing val decrease of 13% to $52.2M (expense). |
| Employees: | 702 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $5,103M as of Mar 31, 2024 |
| Annual revenue (TTM): | $524.07M as of Mar 31, 2024 |
| EBITDA (TTM): | -$402.32M as of Mar 31, 2024 |
| Net annual income (TTM): | -$417.27M as of Mar 31, 2024 |
| Free cash flow (TTM): | -$550.91M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | $88.90M as of Mar 31, 2024 |
| Shares outstanding: | 121,365,555 as of May 1, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.